ArticleExpert review of pharmacoeconomics & outcomes research2019
Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.
Article in Expert review of pharmacoeconomics & outcomes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of moral reasons on orphan drug reimbursement.Orphanet journal of rare diseases · 2021Pooled it
- A Review of Rare Disease Policies and Orphan Drug Reimbursement Systems in 12 Eurasian Countries.Frontiers in public health · 2019Pooled it
- Unleashing the potential: the imperative of political support for health technology assessment in Iran.Health economics review · 2024Article
- Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative.Journal of market access & health policy · 2024Article
- Suitability of the Current Health Technology Assessment of Innovative Artificial Intelligence-Based Medical Devices: Scoping Literature Review.Journal of medical Internet research · 2024Article
- The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries' past health technology assessments.International journal of technology assessment in health care · 2023Article
- The role of Iran's context for the development of health technology assessment: challenges and solutions.Health economics review · 2023Article
- Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment.International journal of technology assessment in health care · 2023Article
- The role of stakeholder involvement in the evolving EU HTA process:Journal of market access & health policy · 2023Article
- Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries.Frontiers in pharmacology · 2022Article
- Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making.PharmacoEconomics - open · 2021Article
- Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.BMC health services research · 2021Article
- Article
- Health technology assessment for pharmaceutical regulation in the European Union: do we need another body?Journal of the Royal Society of Medicine · 2020Article
- Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.Frontiers in pharmacology · 2020Article
- Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future.Frontiers in pharmacology · 2020Review
- Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future.Frontiers in pharmacology · 2020Review
- The Expiry of HumiraFrontiers in pharmacology · 2020Article
- From separation to collaboration: the future of urology.Nature reviews. Urology · 2019Article
Corrections and comments
- Commented on by
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn January 2018 the European Commission published a Proposal for a Regulation on Health Technology Assessment (HTA): 'Proposal for a Regulation on health technology assessment and amending Directive 2011/24/EU'. A number of stakeholders, including some Member States, welcomed this initiative as it was considered to improve collaboration, reduce duplication and improve efficiency. There were however a number of concerns including its legal basis, the establishment of a single managing authority, the preservation of national jurisdiction over HTA decision-making and the voluntary/mandatory uptake of joint assessments by Member States. Areas covered: This paper presents the consolidated views and considerations on the original Proposal as set by the European Commission of a number of policy makers, payers, experts from pricing and reimbursement authorities and academics from across Europe. Expert commentary: The Proposal has since been extensively discussed at Council and while good progress has been achieved, there are still divergent positions. The European Parliament gave a number of recommendations for amendments. If the Proposal is approved, it is important that a balanced, improved outcome is achieved for all stakeholders. If not approved, the extensive contribution and progress attained should be sustained and preserved, and the best alternative solutions found.
Indexed as
Identifiers
30696372What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.